CommentaryOver-Prescription of Acid-Suppressing Medications in Infants: How It Came About, Why It’s Wrong, and What to Do About It
References (50)
- et al.
Efficacy and safety of omeprazole for severe gastroesophageal reflux in children
J Pediatr
(1993) - et al.
Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group
J Pediatr
(2000) - et al.
Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux
J Pediatr
(2003) - et al.
Childhood functional gastrointestinal disorders: neonate/toddler
Gastroenterology
(2006) - et al.
Breath hydrogen excretion in normal newborn infants in response to usual feeding patterns: evidence for “functional lactase insufficiency” beyond the first month of life
J Pediatr
(1984) - et al.
Safety of proton pump inhibitor exposure
Gastroenterology
(2010) - et al.
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa
Gastroenterology
(2000) - et al.
Use of acid-suppressing drugs and the risk of bacterial gastroenteritis
Clin Gastroenterol Hepatol
(2007) - et al.
A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults
J Clin Epidemiol
(2004) - et al.
The role of protein digestibility and antacids on food allergy outcomes
J Allergy Clin Immunol
(2008)
Role of food protein intolerance in infants with persistent distress attributed to reflux esophagitis
J Pediatr
A global evidence-based consensus on the definition of gastroesophageal reflux disease in children
Am J Gastroenterol
Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease
J Pediatr Gastroenterol Nutr
Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children
J Pediatr Gastroenterol Nutr
Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease
J Pediatr Gastroenterol Nutr
Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study
BMC Pediatr
Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis
Clin Pediatr (Phila)
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration
J Pediatr
Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition
J Pediatr Gastroenterol Nutr
Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
Am J Gastroenterol
Outcomes of fundoplication: causes for concern, newer options
Arch Dis Child
Proton pump inhibitor utilization patterns in infants
J Pediatr Gastroenterol Nutr
Infants and proton pump inhibitors: tribulations, no trials
J Pediatr Gastroenterol Nutr
Natural history and familial relationships of infant spilling to 9 years of age
Pediatrics
Cited by (57)
Consensus recommendations on chewing, swallowing and gastrointestinal problems in Phelan-McDermid syndrome
2023, European Journal of Medical GeneticsTrends and Correlates of Early-Life Exposure to Acid-Suppressant Therapy in Israel (2005-2020)
2023, Journal of PediatricsCitation Excerpt :Our study has several strengths. First, we used contemporary data of treatment patterns up to the year 2021, reflecting that despite previous calls to reduce overprescribing,21 the increasing trend continues to date. Second, patients’ clinical and demographic features were explored, detecting risk factors that shed light on potentially behavioral aspects of treatment initiation.
The enigma of gastroesophageal reflux disease among convalescing infants in the NICU: It is time to rethink
2020, International Journal of Pediatrics and Adolescent MedicineRisk Factors for Community-Associated Clostridium difficile Infection in Children
2017, Journal of PediatricsCitation Excerpt :We found that the odds of CA-CDI development following proton pump inhibitor and H2 receptor antagonist exposure were similar to that seen with antibiotic exposures. Given the high frequency with which these medications are prescribed in pediatrics for conditions such as physiologic reflux, these exposures may be a contributor to the increasing number of CA-CDI cases seen in children.22,23 Although C difficile remains a common hospital-associated infection, with great emphasis placed on the importance of infection control measures used to prevent spread in the inpatient setting, our results indicate that many CA-CDI cases may be the result of transmission in the outpatient healthcare setting.
E.H. received a clinical research grant from AstraZeneca Canada and serves as a consultant for Takeda Pharmaceuticals.